Evidence map›Paper›PMID 26475931›Full record

ArticleThe Journal of infectious diseases2016

Herpes Simplex Virus Type-2 Cervicovaginal Shedding Among Women Living With HIV-1 and Receiving Antiretroviral Therapy in Burkina Faso: An 8-Year Longitudinal Study.

Andrea J Low, Nicolas Nagot, Helen A Weiss, Issouf Konate, Dramane Kania, Michel Segondy, Nicolas Meda, Philippe van de Perre, Philippe Mayaud, Yerelon Study Group

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Longitudinal Viral Dynamics in Semen During Early HIV Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Andrea J LowLondon School of Hygiene and Tropical Medicine, United Kingdom.
Nicolas NagotUMR 1058 University of Montpellier Montpellier University Hospital, France.
Helen A WeissLondon School of Hygiene and Tropical Medicine, United Kingdom.
Issouf KonateCentre Muraz, Bobo-Dioulasso, Burkina Faso.
Dramane KaniaCentre Muraz, Bobo-Dioulasso, Burkina Faso.
Michel SegondyUMR 1058 University of Montpellier Montpellier University Hospital, France.
Nicolas MedaCentre Muraz, Bobo-Dioulasso, Burkina Faso.
Philippe van de PerreUMR 1058 University of Montpellier Montpellier University Hospital, France.
Philippe MayaudLondon School of Hygiene and Tropical Medicine, United Kingdom.
Yerelon Study Group
Centre Muraz · BFLondon School of Hygiene & Tropical Medicine · GBUniversité de Montpellier · FRCentre Hospitalier Universitaire de Montpellier · FR

Funding

Medical Research Council MR/K012126/1Wellcome Trust 100714
6 · The paper itself

Abstract

backgroundThe impact of antiretroviral therapy (ART) on herpes simplex virus type-2 (HSV-2) replication is unclear. The aim of this study was to assess factors associated with cervicovaginal HSV-2 DNA shedding and genital ulcer disease (GUD) in a cohort of women living with human immunodeficiency virus type-1 (HIV-1) in Burkina Faso.

methodsParticipants were screened for cervicovaginal HSV-2 DNA, GUD, cervicovaginal and systemic HIV-1 RNA, and reproductive tract infections every 3-6 months over 8 years. Associations with HSV-2 shedding and quantity were examined using random-effects logistic and linear regression, respectively.

resultsOf the 236 women with data on HSV-2 shedding, 151 took ART during the study period. Cervicovaginal HSV-2 DNA was detected in 42% of women (99 of 236) in 8.2% of visits (151 of 1848). ART was associated with a reduction in the odds of HSV-2 shedding, which declined for each year of ART use (odds ratio [OR], 0.74; 95% confidence interval [CI], .59-.92). In the multivariable model, the impact of ART was primarily associated with suppression of systemic HIV-1 RNA (adjusted OR, 0.32; 95% CI, .15-.67). A reduction in the odds of GUD was also observed during ART, mainly in those with HIV-1 suppression (adjusted OR, 0.53; 95% CI, .25-1.11).

conclusionsART is strongly associated with a decrease in cervicovaginal HSV-2 shedding, and the impact was sustained over several years.

Indexed as

AdolescentAdultAnti-HIV AgentsBurkina FasoDNA, ViralFemaleHerpes GenitalisHerpesvirus 2, HumanHIV InfectionsHumansLinear ModelsOdds RatioVirus SheddingYoung AdultAnti-HIV AgentsDNA, ViralantiretroviralsBurkina Fasofemalegenital tractgenital ulcer diseaseherpes simplex virus type-2HIV-1HSV-2

Identifiers

PMID26475931
PMCPMC4747618
OpenAlexW2253517998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.